Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Shares of Hims & Hers Health (HIMS) are down at the time of writing after Morgan Stanley, led by four-star analyst Craig Hettenbach, ...

Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Morgan Stanley also drew scrutiny previously for fielding an all-white, all-male slate of candidates to succeed former CEO ...

Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...